Practical considerations of single-fraction stereotactic ablative radiotherapy to the lung.
Lung Cancer
; 170: 185-193, 2022 08.
Article
in English
| MEDLINE | ID: covidwho-1914798
ABSTRACT
Stereotactic ablative radiotherapy (SABR) is a well-established treatment for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC) and pulmonary oligometastases. The use of single-fraction SABR in this setting is supported by excellent local control and safety profiles which appear equivalent to multi-fraction SABR based on the available data. The resource efficiency and reduction in hospital outpatient visits associated with single-fraction SABR have been particularly advantageous during the COVID-19 pandemic. Despite the increased interest, single-fraction SABR in subgroups of patients remains controversial, including those with centrally located tumours, synchronous targets, proximity to dose-limiting organs at risk, and concomitant severe respiratory illness. This review provides an overview of the published randomised evidence evaluating single-fraction SABR in primary lung cancer and pulmonary oligometastases, the common clinical challenges faced, immunogenic effect of SABR, as well as technical and cost-utility considerations.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Radiosurgery
/
Carcinoma, Non-Small-Cell Lung
/
Small Cell Lung Carcinoma
/
COVID-19
/
Lung Neoplasms
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Lung Cancer
Journal subject:
Neoplasms
Year:
2022
Document Type:
Article
Affiliation country:
J.lungcan.2022.06.014
Similar
MEDLINE
...
LILACS
LIS